SACUBITRIL 50mg. IP + VALSARTAN 26mg. IP

A medication used to treat heart failure with reduced ejection fraction (HFrEF). (Surya Ayalasomayajula, 2017) Sacubitril increases levels of protective peptides that cause vasodilation and help remove excess sodium and water. (Giuseppe Di Tano, 2018) Valsartan blocks the harmful effects of angiotensin II (a hormone that tightens blood vessels), relaxing blood vessels and reducing stress on the heart. (Yasser Khder, 2017) Lowers the risk of hospitalization due to worsening heart failure. Improves symptoms such as shortness of breath, fatigue, and swelling by helping the heart pump more effectively. Demonstrates greater efficacy than enalapril in lowering the risk of death and hospitalization due to heart failure, and all-cause mortality. (Yasser Khder, 2017) Improves circulation and reduces strain on the failing heart. The first novel therapy in a new drug class to improve survival in heart failure with reduced ejection fraction (HFrEF). (Yasser Khder, 2017) A more effective alternative option for angiotensin converting enzyme (ACE) inhibitor enalapril or angiotensin receptor blocker (ARB) valsartan, in the treatment of HFrEF, with proven survival and hospitalization benefits. (McCormack, 2016)